ALK rearrangement was significantly associated with younger age (median age, 57.5 years in the ALK IHC-positive group vs 60 years in the ALK IHC-negative group; P = 0.011), high tumor status (pT4; P = 0.025), high pathologic stage (IIIB; P = 0.002), solid predominant adenocarcinoma with mucin production (P = 0.006), invasive mucinous adenocarcinoma (P = 0.009), and receipt of adjuvant therapy after surgery (P = 0.036). This evidence concerns the gene ALK and mucinous adenocarcinoma.